Recent patient data surrounding Retatrutide , specifically the 120 milligram formulation ZPHC ZPHC, suggest a significant effect on body mass decrease and related health factors. Scientists believe that this dual acting , targeting both GLP-1 and GIP pathways , may provide a major improvement in